CDHR2

Across TCGA pan-cancer cohorts, CDHR2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CDHR2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CDHR2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CDHR2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where CDHR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.959	0.194	.011	20	view →
COAD	DFS	Quartile	III,IV	1.000	0.634	.026	12	view →
PDAC	DFS	Tertile	IV	0.741	0.203	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CDHR2–CCRCC (OS)

Open the CCRCC breakdown →